Becton, Dickinson and Company

(New York Stock Exchange)

Becton, Dickinson and Company (BDX) stock at a glance

Full Becton, Dickinson and Company report
Ticker
BDX
Exchange
New York Stock Exchange
News sentiment Β· last 30 days
+44 Somewhat Bullish β–² +13 vs. previous 30 days
30-day average of 8 articles Β· scale βˆ’100 to +100

Across 8 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Becton, Dickinson and Company news is Somewhat Bullish (+44) on a scale from βˆ’100 to +100. That is up 13 points from the previous 30 days (+31).

+72 Bullish 1 article

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

67
Show Summary
Show Bulletpoints
Detailed View
Neutral 0

Becton Dickinson & Co. stock rises Wednesday, still underperforms market

AI-generated analysis

Shares of Becton Dickinson & Co. (BDX) rose 1.37% to $157.09 on Wednesday, moving within an all-around favorable trading session for the broader stock market. The S&P 500 Index advanced 2.51% to close at 6,782.81, while the Dow Jones Industrial Average gained 2.85% to reach 47,909.92 during the period. Despite this upward momentum, Becton Dickinson & Co. continued to underperform its market benchmarks relative to recent highs. The stock closed for the session at a price that remained 16.15% below its 52-week high of $187.35, a peak which was previously established on February 24. This indicates that even with positive daily performance, the company's share price has not yet recovered to levels reached earlier in the fiscal year. The report notes data specifics and real-time constraints, including intraday data delays of at least 15 minutes per exchange requirements and U.S. stock quote reporting through Nasdaq only.

πŸ“ˆ Becton Dickinson shares rose 1.37% to $157.09 on Wednesday.

πŸ›οΈ S&P 500 Index gained 2.51%, closing at 6,782.81.

πŸ“‰ BDX stock remains 16.15% below its 52-week high.

πŸ“ˆ Becton Dickinson & Co. (BDX) shares rose 1.37% to $157.09 on Wednesday amid a broadly positive market session.

πŸ›οΈ The S&P 500 Index increased 2.51% to close at 6,782.81 during the trading day.

πŸ“‰ Becton Dickinson stock closed 16.15% below its all-time 52-week high of $187.35 reached on February 24th.

πŸ•ŠοΈ The Dow Jones Industrial Average rose 2.85% to reach a level of 47,909.92.

πŸ’Ή BDX continues to underperform the broader market despite the overall stock rally.

Bullish Signals
  • Shares of Becton Dickinson rose 1.37% to $157.09.
  • Stock gained momentum despite trading below its 52-week high.
Risk Factors
  • Shares down 16.15% from 52-week high of $187.35.
  • Stock lagged S&P 500 by 1.14% despite market gain.
  • Continued underperformance relative to broader market gains.
Bullish Signals
  • Shares of Becton Dickinson & Co. BDX rose 1.37% to $157.09 on Wednesday, showing upward momentum despite being below its 52-week high.
  • Becton Dickinson & Co. benefited from an all-around favorable trading session for the broader stock market, with the S&P 500 rising 2.51% and the Dow Jones Industrial Average rising 2.85%.
Risk Factors
  • BDX shares closed 16.15% below its 52-week high of $187.35, indicating continued underperformance relative to its peak reached on February 24th.
  • Despite a gain of 1.37%, the stock still failed to keep pace with broader market gains, posting an outperformance deficit of 1.14% versus the S&P 500 Index SPX's 2.51% rise.
  • The stock remains significantly underperforming the market despite an all-around favorable trading session for the wider market.
Somewhat Bearish -25

BD Rolls Out Next-Gen Medication Dispensing System Across Europe

AI-generated analysis

Becton, Dickinson and Company BDX announced the European launch of its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform, a next-generation medication dispensing system integrating automation with AI-powered insights. The new deployment aims to streamline hospital workflows, reduce inefficiencies, and allow clinicians to focus more on patient care. By combining flexible, stackable configurations for enhanced storage capacity with advanced security features such as RFID badge scanning and wireless barcode scanners, the solution is designed to improve controlled substance management and medication availability while supporting compliance through AWS European Sovereign Cloud infrastructure that handles millions of connected devices across 15 languages. The market response to the announcement saw shares of BDX decline 1.2% on Wednesday, bringing year-to-date losses to 20.4% compared with an industry decline of 2.2% and a S&P 500 drop of 4%. Despite this short-term volatility, analysts note that the rollout strengthens BD’s competitive positioning in the digital healthcare space by creating recurring revenue streams through software and analytics services. The company currently holds a market capitalization of $44 billion, and the innovations build upon a broader European strategy where BD recently received CE Mark approval for its Revello Vascular Covered Stent to expand its peripheral vascular portfolio. Looking ahead, the medication management systems market is projected to be valued at $9.27 billion in 2026 with a compound annual growth rate of 8.9% through 2034, driven by factors such as chronic disease burdens, regulatory support for digitalization, and the need to reduce medication errors. The article also highlights Zacks Investment Research rankings, noting that while BDX carries a Zacks Rank #4 (Sell), other medical sector peers like Phibro Animal Health, GE HealthCare Technologies, and Cardinal Health have received higher ratings following recent earnings beats, suggesting mixed investor sentiment within the broader healthcare technology sector.

πŸ“¦ BD launches Pyxis Pro Dispensing Solution and Incada Connected Care Platform in Europe.

⚠ BDX stock fell 20.4% year-to-date, outperforming industry peers negatively at a Sell rating.

πŸ€– The new system integrates AI insights with automation to streamline pharmacy workflows.

πŸ₯ Enhanced security features like RFID scanning support better controlled substance management.

πŸ“ˆ Global medication management market projected to reach $9.27 billion by 2026.

πŸ“¦ BD announces the European launch of its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform.

πŸ€– The new system integrates automation with AI-powered insights to streamline workflows and reduce inefficiencies.

⚠️ BDX shares fell 1.2% following the announcement, underperforming the S&P 500 in the year-to-date period.

πŸ“‰ Company stock lost 20.4% year-to-date compared to an industry decline of only 2.2%.

πŸ’° BD has a current market capitalization of $44 billion as reported by Zacks Investment Research.

πŸ₯ The Pyxis Pro solution offers flexible, stackable configurations to increase storage within the same footprint.

πŸ›‘οΈ Enhanced security features include RFID badge scanning and wireless barcode scanners for better controlled substance management.

πŸ“Š BD Incada Analytics expands to Europe, providing enterprise-wide visibility into medication inventory using AI.

☁️ The platform is built on Amazon Web Services (AWS) with European Sovereign Cloud for regional data sovereignty compliance.

🌐 Support includes 15 languages with a phased rollout planned over the coming months.

πŸ“ˆ The global medication management systems market was valued at $9.27 billion in 2026 and is projected to grow at an 8.9% CAGR through 2034.

βœ… BD also received CE Mark approval for its Revello Vascular Covered Stent, expanding its peripheral vascular portfolio.

πŸ“‰ Zacks Investment Research currently rates BDX with a Rank #4 (Sell).

πŸ’Š Alternative medical stocks include Phibro Animal Health (Zacks Rank #1), GE HealthCare Technologies (Rank #2), and Cardinal Health (Rank #2).

Bullish Signals
  • BD launches Pyxis Pro and Incada platforms in Europe with automation and AI.
  • New system improves medication availability, efficiency, and patient care benchmarks.
  • European AI rollout strengthens BD's competitive positioning in digital healthcare.
  • Automation and AI analytics drive sustained recurring revenue from software services.
  • BD receives CE Mark approval for Revello Vascular Covered Stent in EU.
  • Approval expands peripheral vascular portfolio and strengthens PAD market presence.
  • Medication management market reaches $9.27B in 2026 with 8.9% CAGR growth.
  • Incada Analytics expands to Europe for enterprise-wide medication inventory visibility.
Risk Factors
  • BDX down 20.4% YTD vs industry's 2.2% decline.
  • Stock holds Zacks Rank #4 (Sell).
  • Shares dropped another 1.2% on Wednesday news.
  • Weak reaction to positive product announcements.
Bullish Signals
  • Becton, Dickinson and Company announced the European launch of its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform, combining automation with AI-powered insights to streamline workflows.
  • The new-generation system empowers customers across Europe to improve medication availability, drive operational efficiency, and elevate patient care by establishing a new benchmark for integrated healthcare operations.
  • In the long run, the European rollout of AI-enabled medication management systems strengthens BD's competitive positioning in the rapidly evolving digital healthcare space.
  • The integration of automation, AI analytics, and cloud infrastructure enhances BD's value proposition, which could drive sustained demand for recurring revenue streams through software, analytics, and service offerings.
  • BD recently announced that it has received CE Mark approval in the European Union for its Revello Vascular Covered Stent intended for treating atherosclerotic lesions.
  • With this approval, BD is expanding its peripheral vascular portfolio and strengthening its presence in the growing peripheral artery disease treatment market.
  • The medication management systems market is valued at $9.27 billion in 2026 and is expected to witness a CAGR of 8.9% through 2034, driven by rising chronic diseases and AI adoption.
  • BD's Incada Analytics platform already established in the United States will be expanded into Europe to provide enterprise-wide visibility into medication inventory using advanced AI capabilities.
Risk Factors
  • Shares of BDX have lost 20.4% year-to-date compared with the industry's 2.2% decline and the S&P 500's 4% fall, indicating significant underperformance relative to peers and the broader market.
  • The stock currently carries a Zacks Rank #4 (Sell), suggesting analysts view it as a poor investment choice compared to better-ranked competitors like Phibro Animal Health and Cardinal Health.
  • Despite positive product news, shares of BDX dropped an additional 1.2% immediately following the announcement on Wednesday, showing weak investor reaction.
  • The article promotes alternative stocks in the same sector with higher Zacks ranks (e.g., #1 Strong Buy, #2 Buy), implicitly signaling that BDX lags in fundamentals or earnings growth potential compared to peers like GE HealthCare and Cardinal Health.
Neutral +5

BD reports lower CEO pay but increases for other execs and the median worker

AI-generated analysis

Becton, Dickinson and Co. (BD), the tenth-largest medical device company globally by revenue, reported its 2025 executive compensation figures in a filing that highlighted a notable divergence between top leadership and median employees. Chairman, CEO and President Tom Polen’s total compensation decreased slightly to just over $17.1 million in 2025 from the prior year, with his salary set at $1.4 million. A significant portion of Polen’s package involved corporate aircraft use, specifically a $216,507 allowance for personal travel and a $236,700 change in pension value, which BD justified as measures for business continuity risk reduction. In contrast to the CEO's slight decline, several other senior executives saw increases: former CFO Christopher DelOrefice received $5.9 million (up 4%), Michael Feld earned $4.1 million, Dr. Michael Garrison took home $3.7 million (up 1%), and Richard Byrd earned $3.4 million (up 4%). The compensation breakdown for these leaders included substantial equity components. For example, DelOrefice’s package contained $3.1 million in stock awards and a $722,500 cash performance bonus before departing the company in December to join Ulta Beauty. Feld, who was promoted to Chief Revenue Officer in October 2025, received a $2 million sign-on bonus prior to joining and earned $1.6 million in stock awards for 2025. Other compensation elements like relocation assistance and car allowances were also included in Feld’s package. The company stated its goal is to balance attracting superior talent with serving the long-term interests of shareholders, emphasizing that a competitive program is critical for delivering returns. Beyond executive pay, BD disclosed data regarding median employee compensation as required by the U.S. Securities and Exchange Commission. The median annual total compensation for all employees excluding Polen was $45,831 in 2025, representing a 5% increase from $43,763 the previous year. Consequently, the ratio of CEO pay to median employee pay narrowed from 396:1 the prior year to 374:1 for 2025, despite the overall dollar amount paid to top leadership remaining higher in absolute terms compared to some peers. The company did not specify job titles or locations for its median employees. In recognition of these practices, BD investors overwhelmingly voted in support of the company’s executive pay proposals at the annual meeting held on January 27, 2026.

πŸ“Š Annual sales reached $21.8 billion, an 8% increase over prior year.

πŸ’° CEO compensation fell to $17.1 million amid increased median worker pay of 5%.

βš–οΈ CEO-to-worker pay ratio narrowed from 396:1 to 374:1 with strong investor support.

πŸ“Š BD (Becton, Dickinson and Co.) generated $21.8 billion in annual sales for its latest fiscal year ending Sept. 30, 2025, representing an 8% increase.

πŸ‘” CEO Tom Polen’s total compensation decreased to just over $17.1 million in 2025, a 1% decline from the previous year.

✈️ Polen received $341,251 in other compensation, which included significant personal use of corporate aircraft and a company car for security reasons.

πŸ‘¨β€πŸ’Ό Former CFO Christopher DelOrefice earned $5.9 million in 2025 before leaving the company to join Ulta Beauty.

πŸ“ˆ New EVP Michael Feld received $4.1 million in 2025, which included $602,054 in other compensation primarily for relocation assistance.

πŸ’΅ Other key executives, including Dr. Michael Garrison and Richard Byrd, saw their total compensation increase by 1% and 4% respectively for 2025.

πŸ›‘οΈ BD stated that its executive compensation program aims to serve the long-term interests of shareholders by attracting and retaining superior talent.

πŸ‘₯ The median employee’s annual total compensation rose to $45,831, which is a 5% increase from the previous year of $43,763.

βš–οΈ BD’s CEO-to-median-worker pay ratio narrowed from 396:1 last year to 374:1 in 2025.

βœ… Overwhelming support for executive pay practices was noted among BD investors at the January 27, 2026 annual meeting.

Bullish Signals
  • BD sales increased 8% to $21.8B for FY ending Sept. 30, 2025.
  • Company ranked 10th-largest medical device firm globally in 2025.
  • Median employee pay rose 5% YoY from $43,763 to $45,831.
  • CEO pay ratio narrowed from 396:1 to 374:1.
  • CFO DelOrefice compensation up 4% despite departure.
  • CRO Feld received $2M sign-on bonus in October 2025.
  • Majority of investors approved executive pay practices at Jan. 27, 2026 meeting.
Risk Factors
  • Median pay rose 5% to $45k, straining budget and margins.
  • CEO-to-worker ratio dropped to 374:1, risking governance scrutiny.
  • Former CFO exit creates succession risk amid $5.9M transition costs.
  • CEO pension changes and $216k aircraft use raise cost questions.
  • $2M Life Sciences sign-on bonus suggests high talent acquisition costs.
  • Competitive pay retention plans may increase expenses vs competitors.
Bullish Signals
  • BD increased its annual sales by 8% to $21.8 billion for the fiscal year ending Sept. 30, 2025, demonstrating strong revenue growth.
  • The company ranked as the 10th-largest medical device company globally according to Medical Design & Outsourcing's 2025 Medtech Big 100 ranking by revenue.
  • Median employee compensation increased by 5% from $43,763 to $45,831 year-over-year, reflecting improved pay for the broader workforce.
  • The CEO pay ratio narrowed from 396:1 to 374:1, indicating a more sustainable and shareholder-friendly executive compensation structure.
  • BD EVP and CFO Christopher DelOrefice's total compensation rose by 4% despite his departure, suggesting high demand for top talent in the medtech sector.
  • BD EVP Michael Feld joined the company with sign-on bonuses worth $2 million when he was promoted to CRO in October 2025.
  • A majority of investors voted in favor of BD's executive pay practices at the Jan. 27, 2026 annual meeting, signaling shareholder approval of current compensation strategies.
  • BD emphasizes that its compensation program serves long-term shareholder interests and is critical for attracting and retaining superior talent.
Risk Factors
  • BD reported an increase in median worker pay of 5% to $45,831, which may put pressure on the company's overall compensation budget and margins.
  • The CEO-to-median-worker pay ratio stands at 374:1, down from 396:1 previously, potentially highlighting a disparity that could be scrutinized for governance concerns.
  • Former CFO Christopher DelOrefice departed in December to join Ulta Beauty, creating succession risk as he transitioned to new executive compensation packages totaling $5.9 million.
  • CEO Tom Polen received $236,700 in pension value changes and significant personal use of corporate aircraft ($216,507 for 2025), raising questions about cost-efficiency and shareholder interest.
  • Life Sciences President Michael Feld joined BD only to receive a $2 million sign-on bonus in 2024, suggesting high talent acquisition costs that may impact profitability.
  • BD's focus on executive retention through competitive pay packages may lead to increased compensation expenses compared to competitors like Johnson & Johnson or Boston Scientific.
Bullish +72

3 Beaten-Down Dividend Aristocrats to Scoop Up While Wall Street Chases AI Stocks Into a Cliff

AI-generated analysis

The article identifies three beaten-down Dividend Aristocrat stocksβ€”PepsiCo (PEP), Hormel Foods (HRL), and Becton Dickinson (BDX)β€”as attractive investment opportunities following a rotation of capital away from overhyped AI sectors. These companies are viewed as undervalued compared to the broader market, trading at steep discounts that reflect specific, now-subsiding headwinds. The author suggests that if investors anticipate a potential slowdown in the AI rally, these dividend aristocrats offer a stable alternative with the potential for recovery and steady income through reinvestable yields. PepsiCo is highlighted as having suffered from market overreaction to concerns regarding revenue growth and GLP-1 drug popularity, resulting in a valuation of 17 times forward earnings compared to historical highs. The stock, a Dividend King with 53 consecutive years of dividend growth, offers a yield near 3.75% that approaches current Treasury yields but provides greater upside potential and inflation hedging. Analysts expect the slump to be temporary, with a full recovery potentially occurring within the next 24 months if lower Treasury yields materialize. Hormel Foods is noted for underperforming significantly, down over 52% in the past five years, due to input cost inflation and a costly 2021 acquisition of Planters that increased debt and reduced cash reserves. The company recently posted a plunge in net income from $1 billion in 2022 to $478 million in 2025. However, the current price around $22 is viewed as a bottom, offering a 5.22% dividend yield at only 15 times forward earnings, with expectations that pricing power will eventually catch up to costs and commodity relief will arrive by late 2026. Becton Dickinson (BDX) has faced sequential challenges including tariff impacts, reduced research funding, and leadership changes, causing a 20% plunge from its prior sideways trading range. The stock now trades at just 12 times forward earnings and historically even lower when adjusting for non-recurring expenses, representing a significant discount to its long-term average of 21 times adjusted earnings. As a Dividend King with 53 years of consecutive dividend growth, BDX offers a 2.69% yield on the lowest side of historical valuations, with analysts expecting EPS and revenue recovery starting from fiscal year 2027 as macroeconomic pressures like budget cuts and tariff chaos fade.

πŸ’° PepsiCo trades at 17x earnings with a 3.75% yield despite GLP-1 headwinds.

πŸ– Hormel offers 5.22% yield and potential upside as costs normalize by FY2026/2027.

πŸ”¬ Becton Dickinson provides a 30% payout ratio with earnings recovery expected in 2027.

πŸ“‰ Wall Street capital is rotating into neglected Dividend Aristocrats like PepsiCo (PEP), Hormel Foods (HRL), and Becton Dickinson (BDX) as they trade at steep discounts.

🧬 PepsiCo's stock has faced headwinds from GLP-1 drugs slowing growth expectations, though the company still dominates snack aisles.

πŸ’° PEP trades at just 17 times forward earnings compared to its historical valuation and offers a 3.75% dividend yield near Treasury bond rates.

πŸ† PepsiCo is a Dividend King with 53 consecutive years of annual dividend increases despite recent market skepticism.

πŸ“‰ Hormel Foods stock has underperformed over the past five years, dropping more than 52% due to inflation costs and high debt from acquisitions.

πŸ’Έ Net income for Hormel plunged from $1 billion in 2022 to $478 million recently, but revenue has remained stable around $12 billion.

🌱 A recovery for Hormel is expected once input costs adjust and the company sheds low-margin businesses like whole-bird turkey by FY2026/2027.

πŸ’° HRL offers a 5.22% dividend yield and trades at just 15 times forward earnings, potentially providing significant long-term upside if it bottoms at $22.

πŸ“‰ Becton Dickinson (BDX) stock has declined over the past year due to compounded challenges from China demand, research funding cuts, tariffs, and leadership changes.

πŸ’° BDX is a Dividend King with 53 consecutive years of dividend growth and trades at just 11 times earnings after stripping non-recurring expenses.

πŸ”’ The company's payout ratio is only 30%, leaving ample room for future dividend increases before hitting the historical ceiling.

πŸ“ˆ Analysts expect EPS and revenue recovery for BDX to begin starting in fiscal year 2027 as tariff chaos subsides.

πŸ€– Investors are positioning for a potential fade in AI stocks, making these undervalued defensive dividends attractive alternatives.

πŸ›‘οΈ Both PepsiCo and Hormel are considered Dividend Aristocrats, while Becton Dickinson is a Dividend King, highlighting their reliability for income investors.

πŸ“‰ Treasury yields dropping further could act as a catalyst to re-rate PEP stock upward given its current yield advantage over T-Notes.

Bullish Signals
  • BDX trades at 12x forward earnings with historical average of 21x.
  • BDX is a Dividend King with 53 years of dividend growth.
  • Analysts expect BDX EPS and revenue recovery from fiscal year 2027.
  • HRL offers a robust 5.22% dividend yield after a 52% drop.
  • Hormel expects commodity relief in the back half of 2026.
  • PEP trades at 17x forward earnings with a 3.75% dividend yield.
  • These Dividend Aristocrats offer high-yield safety amidst AI stock chasing.
  • Lower Treasury yields could drive massive inflows into PepsiCo.
Risk Factors
  • PepsiCo stock over-discounted due to GLP-1 drug revenue slowdown fears.
  • Hormel net income plummeted from $1B in 2022 to $478M in 2025.
  • Hormel cash dropped $1.73B to $635M and debt hit $3.3B post-Planters deal.
  • Hormel recorded $54M net interest losses amid record rate hikes.
  • BDX stock fell 20% with recovery delayed until FY2027.
Bullish Signals
  • Becton Dickinson (BDX) trades at just 12 times forward earnings after factoring out non-recurring expenses, offering significant upside potential as historical valuations range around 21 times earnings.
  • BDX has a Dividend King status with 53 consecutive years of dividend growth, currently yielding 2.69% with room for expansion given the low payout ratio of just 30%.
  • Tariff chaos and budget cuts are now behind BDX, with analysts expecting EPS and revenue recovery to begin from fiscal year 2027 onwards.
  • Hormel Foods (HRL) trades at only 15 times forward earnings with a robust 5.22% dividend yield, suggesting the stock has bottomed out after being beaten down by over 52% in five years.
  • Hormel's turnaround is supported by expected commodity relief in the back half of 2026 and strategic portfolio pruning to improve margins.
  • PepsiCo (PEP) trades at just 17 times forward earnings, with dividends yielding 3.75%, comparable to T-Notes which still lack inflation hedging and upside potential.
  • Dividend Aristocrats like PEP, HRL, and BDX are trading at steep discounts while Wall Street chases AI stocks, creating a rotational opportunity for capital seeking safer, high-yield assets.
  • The positive catalyst of lower Treasury yields could drive massive inflows into PepsiCo, re-rating the stock upward as inflation hedges gain favor over risk-free rates.
Risk Factors
  • PepsiCo's stock has been significantly beaten down due to revenue growth slowdown concerns related to GLP-1 drugs, causing the market to over-discount the stock despite it dominating snack aisles.
  • Hormel Foods (HRL) suffered a net income plunge from $1 billion in 2022 to $478 million in 2025 due to higher input costs and customers unwillingness to buy at elevated prices, even though revenue remained stable at $12 billion.
  • Hormel Foods' balance sheet was severely damaged by the $3.35 billion acquisition of the Planters snack nut portfolio in 2021, which reduced cash from $1.73 billion to just $635 million while increasing debt to $3.3 billion amid rising interest rates.
  • The acquisition impact is still costing Hormel Foods dearly with net interest losses of $54 million in the last fiscal year due to record interest rate hikes following the debt loading.
  • Becton Dickinson (BDX) traded sideways from 2018 to 2025 before plunging by 20% and has yet to recover, indicating prolonged stagnation without significant upside realized so far.
  • BDX lost ground due to a convergence of negative factors including China-related issues, research funding concerns, tariff pressures, and a leadership shake-up that arrived in near-sequential waves.
  • Analysts expect BDX's EPS and revenue recovery not until FY2027 onwards, suggesting the downside catalysts have created a delayed recovery timeline rather than an immediate rebound.
  • Despite positive framing about cheap valuations, Hormel Foods operates with a payout ratio and earnings situation that suggests significant operational headwinds must resolve before the stock can sustain growth.
Somewhat Bearish -40

Argus Lowers its Price Target on Becton, Dickinson and Company (BDX) to $180 from $230

AI-generated analysis

Argus Research has downgraded its price target for Becton, Dickinson and Company (NYSE:BDX) from $230 to $180 while maintaining a Buy rating, driven by the company's strategic shift toward a pure-play medical technology model following the spin-off of its Biosciences and Diagnostics Solutions segments. The analyst firm highlights that the stock currently trades at 11.5 times forward earnings, which is significantly below the 20.4x average for comparable companies in its MedTech coverage universe, suggesting it remains undervalued despite the rating adjustment. This financial restructuring aligns with CEO Tom Polen's comments on stronger-than-expected performance in Q1, where adjusted earnings per share of $2.91 exceeded analyst expectations of $2.81, and revenue reached $5.3 billion against a forecast of $5.15 billion. The company continues to innovate within its new strategic direction, evidenced by recent FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system, the first of its kind designed for powered lavage to enhance surgical efficiency and safety. This approval underscores the management's focus on innovation and growth in key markets as part of the transition to what they call "New BD." While Argus acknowledges BDX's investment potential, it contrasts this with a broader market view that certain AI stocks currently offer greater upside, though this specific comparison does not alter the positive assessment of BDX's current valuation metrics relative to peers.

πŸ“‰ Argus lowered BDX price target to $180 after spin-off and lower valuation multiple.

⭐ Firm maintains Buy rating as CEO highlights strong earnings beat and growth execution.

πŸ”„ Company pivots to pure-play medical technology, focusing on innovation and core operations.

🦠 FDA cleared new Surgiphor 1000mL irrigation system to enhance surgical safety.

- πŸ“‰ Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 as of March 23, 2026.

- ⭐ The firm maintained a Buy rating for the company following its strategic transition toward a pure-play medical technology model.

- πŸ”„ This pivot involves the spin-off of its Biosciences and Diagnostics Solutions businesses, reshaping the company's core operations.

- πŸ’Ή BDX currently trades at 11.5 times forward earnings, which is significantly below the 20.4x average for the broader MedTech coverage universe.

- πŸš‘ The FDA granted 510(k) clearance for Surgiphor 1000mL, a new antimicrobial irrigation system designed for powered lavage to enhance surgical safety.

- πŸ“Š In its latest quarter, Becton, Dickinson and Company reported adjusted earnings per share of $2.91, beating the analyst consensus of $2.81.

- πŸ’° Revenue for the period reached $5.3 billion, surpassing the expected estimate of $5.15 billion.

- πŸ—£οΈ CEO Tom Polen characterized the results as "stronger-than-expected," attributing the performance to execution and growth in key markets.

- πŸ”„ Management emphasized that the company is "fully pivoting to New BD" with a focus on innovation, productivity, and long-term expansion.

- πŸ”¬ Becton, Dickinson and Company develops and sells medical devices, laboratory equipment, and diagnostic products on a global scale.

- πŸ“‰ Analysts at Argus view the stock as undervalued relative to peers due to its lower valuation multiple post-spin-off.

- ⚠️ The article notes that the spin-off marks a significant structural change reducing exposure to certain diagnostics segments.

- 🏭 The company is now concentrating its efforts on core medtech operations following the separation of non-core assets.

Bullish Signals
  • Becton Dickinson (NYSE:BDX) named one of 7 most undervalued blue chips.
  • Argus maintains Buy rating citing successful pure-play medtech transition.
  • Stock trades at 11.5x earnings versus 20.4x sector average.
  • FDA cleared Surgiphor 1000mL antimicrobial irrigation system in March 2026.
  • Q1 adjusted EPS of $2.91 beat consensus estimate of $2.81.
Risk Factors
  • Argus cut BDX price target from $230 to $180 on March 23, 2026.
  • Significant reduction in expected upside for Becton, Dickinson and Company.
Bullish Signals
  • Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the 7 Most Undervalued Blue Chip Stocks to Invest In.
  • Argus maintained a Buy rating on BDX despite lowering the price target, citing the company's successful transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business.
  • The stock trades at about 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe, highlighting its undervalued status.
  • On March 23, 2026, the company received FDA 510(k) clearance for Surgiphor 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage aimed at improving surgical efficiency and safety.
  • Becton, Dickinson and Company reported Q1 adjusted EPS of $2.91, beating the $2.81 consensus estimate, on revenue of $5.3B versus $5.15B expected.
  • CEO Tom Polen described Q1 results as 'stronger-than-expected' performance driven by execution and growth across key markets.
  • The company is fully pivoting to 'New BD' following its portfolio changes, with a clear focus on innovation, productivity, and long-term growth.
Risk Factors
  • Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 on March 23, 2026, indicating a significant reduction in expected upside.
Somewhat Bearish -25

Argus Lowers its Price Target on Becton, Dickinson and Company (BDX) to $180 from $230

AI-generated analysis

Argus lowered its price target on Becton, Dickinson and Company (NYSE:BDX) from $230 to $180 on March 23, 2026, while maintaining a Buy rating. The firm cited the company's strategic transition toward a pure-play medical technology model following the spin-off of its Biosciences and Diagnostics Solutions business as a key factor in this adjustment. According to Argus, BDX currently trades at approximately 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe. Despite the downward revision to the price target, the company maintains its positive stance, acknowledging the risks and potential associated with investing in BDX. In recent financial developments, Becton Dickinson announced it received FDA 510(k) clearance on March 23, 2026, for Surgiphor 1000mL, a system described as the first 1000 mL antimicrobial irrigation system designed for powered lavage intended to improve surgical efficiency and safety. Earlier in the month, the company reported Q1 adjusted earnings per share (EPS) of $2.91, surpassing the consensus estimate of $2.81 on revenue of $5.3 billion compared to the expected $5.15 billion. CEO Tom Polen noted that these results reflected stronger-than-expected performance driven by execution and growth across key markets, emphasizing that the company is fully pivoting toward "New BD" with a focus on innovation, productivity, and long-term growth as part of its portfolio changes. The article further highlights that Becton Dickinson develops and sells medical devices, laboratory equipment, and diagnostic products globally. It concludes with promotional content for an investment platform claiming certain AI stocks offer higher returns with 10,000% upside potential and provides a list of other recent Wall Street bullish moves on defense and aerospace companies such as L3Harris Technologies, Lockheed Martin, Northrop Grumman, General Dynamics, and Rocket Lab. A disclosure states there is no conflict of interest or affiliate relationship disclosed within the content regarding BDX specifically.

πŸ“‰ Argus lowered the price target to $180 while keeping a Buy rating.

βœ… Q1 adjusted EPS beat estimates at $2.91 on $5.3B revenue.

πŸ”„ The company pivots to pure-play MedTech following the Biosciences spin-off.

πŸ“‰ Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 while maintaining a Buy rating.

πŸ”„ The downgrade cites the company's transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business.

πŸ“Š BDX currently trades at approximately 11.5 times forward earnings, which is below the 20.4 times average for its MedTech coverage universe.

βœ… On March 23, 2026, the company received FDA 510(k) clearance for Surgiphor 1000mL, a new antimicrobial irrigation system for powered lavage.

πŸ’° Becton, Dickinson and Company reported Q1 adjusted EPS of $2.91 against a consensus estimate of $2.81 on revenue of $5.3B versus $5.15B expected.

πŸš€ CEO Tom Polen stated results reflected stronger-than-expected performance driven by execution and growth across key markets.

πŸ”„ Management confirmed the company is fully pivoting to New BD with a focus on innovation, productivity, and long-term growth.

🏭 Becton, Dickinson and Company develops and sells medical devices, laboratory equipment, and diagnostic products globally.

⚠️ The article notes that while acknowledging risk and potential in BDX as an investment, some conviction lies in AI stocks holding greater promise for higher returns.

πŸ’‘ The article references a report about a cheapest AI stock with alleged 10,000% upside potential, suggesting a comparison to BDX.

Risk Factors
  • Argus cut price target on BDX by $50 to $180.
  • BDX shows inferior growth potential versus AI competitors.
  • Valuation at 11.5x earnings may cap upside gains.
  • Spin-off creates structural disruption and integration risks.
Bullish Signals
  • Argus maintained a 'Buy' rating on Becton, Dickinson and Company (BDX) despite lowering the price target, citing the company's successful transition toward a pure-play medtech model following its strategic spin-offs.
  • The stock trades at 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe, suggesting it may be undervalued relative to peers.
  • BDX recently announced FDA 510(k) clearance for Surgiphor 1000mL, marking the first of its kind antimicrobial irrigation system designed to improve surgical efficiency and safety.
  • First-quarter results exceeded analyst expectations with adjusted EPS of $2.91 versus a consensus estimate of $2.81, driven by stronger-than-expected performance across key markets.
  • The company reported revenue of $5.3 billion, surpassing the $5.15 billion expected, demonstrating robust operational execution and growth in its portfolio.
Risk Factors
  • Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180, a significant reduction of $50 per share.
  • Analysts view AI stocks as having greater promise for delivering higher returns in a shorter time frame than BDX, suggesting inferior growth potential relative to competitors.
  • The stock is considered undervalued at only 11.5 times forward earnings compared to the 20.4x average for its MedTech coverage universe, which may limit upside despite perceived undervaluation claims.
  • Argus cited a transition toward a pure-play medtech model following a spin-off of its Biosciences and Diagnostics Solutions business, indicating ongoing structural disruption and integration risks.
Slightly Bullish +25

Becton Dickinson Product Launches Aim To Deepen Recurring Hospital Revenue

AI-generated analysis

Becton Dickinson (NYSE:BDX) recently received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system and launched the BD Vacutainer Urine Complete Cup Kit, moves designed to strengthen recurring hospital revenue streams. These new product launches target specific areas of hospital workflow where infection control and diagnostic accuracy are paramount: powered lavage in operating rooms and pre-analytical urine collection in clinical labs. The Surgiphor system is positioned as a differentiated option for surgeons and procurement teams seeking standardization, while the Urine Complete Cup Kit aims to reduce specimen contamination, minimize redraws, and streamline manual handling by combining multiple tubes into a single closed-transfer system. For investors, these additions represent a strategic expansion within Becton Dickinson's core medical devices, diagnostics, and interventional products franchises. The primary investment thesis revolves around whether these new offerings can help the company win or retain customer contracts against established peers like Medtronic, Johnson & Johnson, and Abbott in consumables-heavy categories that generate steady recurring revenue. Management commentary regarding utilization rates, hospital contract wins, and attach rates within existing accounts will likely be key indicators of commercial success. Analysts note that while earnings have grown over the past five years and forecasts suggest continued growth, these specific product launches are critical to supporting future revenue through increased consumables usage in standardization-focused medical settings. Despite the positive product momentum, two significant risks remain highlighted for Becton Dickinson: its balance sheet flexibility and execution challenges. Analysts have flagged that the company's debt is not well covered by operating cash flow, meaning additional product launches do not eliminate the necessity of monitoring funding costs and financial stability. Furthermore, there is execution risk associated with new product rollouts, including potential hurdles in training healthcare staff, navigating reimbursement protocols, and integrating new technologies into existing hospital systems. If hospitals remain cautious about adopting new protocols or if customers are slow to change established practices, the commercial impact of these launches could be limited. Success will likely depend on whether Becton Dickinson can build full platforms rather than isolated SKUs and effectively compete in a market where product design significantly influences purchasing decisions.

βœ… FDA cleared Surgiphor and new urine kits to boost surgical safety and diagnostics.

⚠ Execution risks include reimbursement hurdles and potential competition from major medical device peers.

πŸ“‰ Balance sheet concerns persist despite strong earnings growth and a 2.51% dividend yield.

🩺 Becton Dickinson (NYSE:BDX) received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system to expand its surgical solutions portfolio.

πŸ§ͺ The company also launched the BD Vacutainer Urine Complete Cup Kit to improve urine collection and diagnostic workflows in clinical labs.

πŸ₯ These new product launches focus on enhancing patient safety, workflow efficiency, and diagnostic accuracy across surgical and laboratory settings.

πŸ’Ό Surgiphor provides a differentiated option for powered lavage, addressing surgeon and procurement concerns regarding standardization and infection control.

πŸ§ͺ The urine collection kit consolidates multiple tubes into a closed-transfer system to reduce specimen contamination, redraws, and manual handling errors.

πŸ”„ These consumables-focused offerings align with Becton Dickinson's core franchise in medical devices, diagnostics, and interventional products.

βš–οΈ Investors are advised to monitor how widely these products are adopted in operating rooms and clinical labs compared to competitors like Medtronic, Johnson & Johnson, and Abbott.

πŸ“‰ Analysts have flagged that BD's debt is not well covered by operating cash flow, indicating a need to monitor balance sheet flexibility regardless of product launches.

⚠️ Execution risks such as training requirements, reimbursement challenges, and integration into existing hospital systems could limit the commercial impact of these new products.

πŸ“ˆ Earnings have grown over the past five years and are forecast to grow further, supporting the case for recurring revenue growth in consumables categories.

πŸ’° Becton Dickinson is trading at what analysts assess as good value compared with peers and offers a reliable 2.51% dividend yield.

πŸ“Š Management commentary on hospital contracts, utilization rates, and any follow-on product extensions will be key metrics to track for investors.

βš™οΈ The focus on operating room irrigation and urine pre-analytics represents specific niches that may not be fully captured by broader industry narratives around biologics delivery.

πŸ—οΈ Sustained growth depends on whether these launches help BD win or retain broader customer contracts against peers in consumables-heavy categories.

Bullish Signals
  • FDA clearance expands surgical solutions portfolio with Surgiphor.
  • New urine kit reduces contamination risk in diagnostic workflows.
  • Aligns with medical franchise to support future revenue growth.
  • Trading at good value with reliable 2.51% dividend.
  • Earnings grew 5 years and forecast further expansion.
Risk Factors
  • BD debt is poorly covered by operating cash flow.
  • Slow adoption may limit commercial impact of new products.
  • Market focus on specific niches misses broader biologics narratives.
  • Slower product uptake could challenge BD's growth acceleration.
  • Peer competition in consumables threatens customer contract retention.
Bullish Signals
  • Becton Dickinson (NYSE:BDX) received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system, which expands its surgical solutions portfolio and provides a differentiated option in powered lavage.
  • The company also launched the BD Vacutainer Urine Complete Cup Kit, targeting improvements in urine collection and diagnostic workflows by packaging multiple tubes into a single system to reduce contamination risk and manual handling.
  • These new offerings align closely with BD's core franchise in medical devices and diagnostics, supporting future revenue growth and deeper recurring consumables usage as hospitals emphasize infection control and standardized testing.
  • Analysts note that Becton Dickinson is trading at good value compared with peers while offering a reliable 2.51% dividend, which may appeal to investors seeking established franchises in medical supplies.
  • Earnings have grown over the past 5 years and are forecast to grow further, reinforcing the case that BD can build on existing strengths in recurring revenue categories alongside consumables-focused launches.
Risk Factors
  • ⚠️ Analysts have flagged that BD's debt is not well covered by operating cash flow, indicating potential balance sheet fragility and funding cost risks.
  • Execution risk surrounds new product rollouts, including training, reimbursement, and integration into existing hospital systems, which could limit commercial impact if customers are slow to adopt new protocols.
  • The specific focus on operating room irrigation and urine pre-analytics may not be fully captured in broader market narratives about biologics delivery or decentralized care.
  • If adoption of Surgiphor and the Vacutainer Urine Complete Cup Kit is slower than expected, it could challenge assumptions regarding BD's ability to accelerate growth through these new products.
  • Rising competitive threats from peers like Medtronic, Johnson & Johnson, and Abbott in consumables-heavy categories could hinder BD's ability to win or retain broader customer contracts.